Kyverna Therapeutics Inc Sustainability Reports
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Its pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies engineered to achieve deep immune system resets.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00RCYMHS0
1 reports from 2024 to 2024
Company Profile
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Its pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies engineered to achieve deep immune system resets.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
